Understanding orforglipron clinical trials is essential for appreciating the comprehensive research behind this investigational medication. The orforglipron clinical trial program includes multiple Phase 3 studies evaluating efficacy and safety in type 2 diabetes and obesity. This article explores the key orforglipron clinical trials and their findings.
Orforglipron Clinical Trials: Overview
The orforglipron clinical trials program has been extensive, with studies enrolling over 10,000 patients across multiple indications. The orforglipron clinical trial portfolio includes two main programs: ACHIEVE (for type 2 diabetes) and ATTAIN (for obesity).
These orforglipron clinical trials have been designed to evaluate:
- Efficacy in improving glycemic control
- Weight loss outcomes
- Safety and tolerability
- Comparison to other treatments
- Long-term outcomes
The orforglipron clinical trial results have been published in major medical journals and presented at international conferences, providing comprehensive data on the medication's performance.
ACHIEVE-1 Orforglipron: Type 2 Diabetes Trial
ACHIEVE-1 orforglipron evaluated the medication in adults with type 2 diabetes inadequately controlled with diet and exercise alone. The ACHIEVE-1 orforglipron study enrolled 559 participants, making it a substantial orforglipron clinical trial. The trial is registered on ClinicalTrials.gov, where protocol and outcome details are publicly accessible.
Eli Lilly announced ACHIEVE-1 topline clinical trial results for orforglipron in type 2 diabetes in April 2025. The full ACHIEVE-1 orforglipron results were presented at the American Diabetes Association (ADA) Scientific Sessions and published in the New England Journal of Medicine in June 2025.
The ACHIEVE-1 orforglipron trial demonstrated significant improvements in:
- Hemoglobin A1c reduction
- Fasting plasma glucose
- Body weight reduction
- Overall glycemic control
The ACHIEVE-1 orforglipron results established the efficacy of orforglipron as monotherapy for type 2 diabetes, providing important data for the orforglipron clinical trial program.
ACHIEVE-3 Orforglipron: Comparison Trial
ACHIEVE-3 orforglipron compared orforglipron to oral semaglutide in people with type 2 diabetes inadequately controlled with metformin. This orforglipron clinical trial provided head-to-head comparison data between two oral GLP-1 medications.
Eli Lilly announced ACHIEVE-3 clinical trial results for orforglipron compared to oral semaglutide in September 2025. The ACHIEVE-3 orforglipron trial demonstrated comparable efficacy between the two medications, with orforglipron showing advantages in dosing convenience.
The ACHIEVE-3 trial orforglipron results help healthcare providers understand how orforglipron compares to established oral GLP-1 therapy, informing treatment decisions in clinical practice.
ATTAIN-1 Orforglipron: Obesity Trial
ATTAIN-1 orforglipron evaluated the medication in adults with obesity or overweight without type 2 diabetes. This orforglipron clinical trial focused specifically on weight management outcomes.
Eli Lilly announced ATTAIN-1 topline trial results for orforglipron in obesity in August 2025. The ATTAIN-1 orforglipron full results were presented at the European Association for the Study of Diabetes Annual Meeting and published in the New England Journal of Medicine in September 2025.
The ATTAIN-1 orforglipron trial demonstrated:
- Significant weight loss compared to placebo
- Clinically meaningful weight reduction
- Favorable safety profile
- Dose-dependent efficacy
The ATTAIN-1 orforglipron results support the use of orforglipron for obesity treatment, providing key data for regulatory submissions.
ATTAIN-2 Orforglipron: Obesity with Type 2 Diabetes
ATTAIN-2 orforglipron evaluated the medication in adults with obesity or overweight who also had type 2 diabetes. This orforglipron clinical trial addressed the common co-occurrence of these conditions.
Eli Lilly announced ATTAIN-2 topline results in August 2025, with full ATTAIN-2 orforglipron results presented at ObesityWeek annual conference and published in The Lancet in November 2025.
The ATTAIN-2 orforglipron trial showed that orforglipron could effectively address both conditions simultaneously, demonstrating improvements in both glycemic control and weight management.
Orforglipron Clinical Trial Phase 3: Comprehensive Program
The orforglipron phase 3 program represents a comprehensive evaluation of the medication across multiple patient populations and clinical scenarios. The orforglipron phase 3 trial portfolio includes:
- ACHIEVE-1: Type 2 diabetes monotherapy
- ACHIEVE-2: Type 2 diabetes vs dapagliflozin
- ACHIEVE-3: Type 2 diabetes vs oral semaglutide
- ACHIEVE-4: Type 2 diabetes (results expected first half 2026)
- ACHIEVE-5: Type 2 diabetes with insulin glargine
- ATTAIN-1: Obesity without type 2 diabetes
- ATTAIN-2: Obesity with type 2 diabetes
- ATTAIN-MAINTAIN: Weight loss maintenance
This extensive orforglipron phase 3 program provides robust evidence supporting the medication's efficacy and safety across diverse patient populations.
Orforglipron Clinical Trial Sign Up: Participation
For patients interested in participating in orforglipron clinical trials, understanding "orforglipron clinical trial sign up" processes is important. Orforglipron clinical trial participation typically involves:
- Meeting eligibility criteria
- Informed consent process
- Regular study visits
- Monitoring and follow-up
Information about "orforglipron clinical trial sign up" can be found through clinical trial registries, healthcare providers, or Eli Lilly clinical trial information resources.
Orforglipron Clinical Trial Results: Key Findings
The orforglipron clinical trial results from completed Phase 3 studies demonstrate:
- Efficacy: Significant improvements in glycemic control and weight loss
- Safety: Generally well-tolerated with manageable side effects
- Convenience: Oral administration offers advantages over injectable alternatives
- Comparability: Similar efficacy to other GLP-1 medications
The orforglipron clinical trial results support the medication's potential as an effective treatment for type 2 diabetes and obesity, with the convenience of oral administration.
Orforglipron Phase 3 Dose Optimization
The orforglipron phase 3 dose optimization has been an important aspect of the clinical trial program. Multiple orforglipron phase 3 dose levels have been evaluated to identify optimal dosing strategies for different patient populations.
The orforglipron phase 3 dose findings inform:
- Starting dose recommendations
- Titration schedules
- Maximum effective doses
- Dose-dependent efficacy and safety
The orforglipron phase 3 dose data supports flexible dosing options, allowing healthcare providers to individualize treatment based on patient needs.
Future Orforglipron Clinical Trials
Additional orforglipron clinical trials are ongoing or planned, including:
- ACHIEVE-4: Results expected in first half of 2026
- ATTAIN program extensions evaluating:
- Obstructive sleep apnea
- Hypertension
- Osteoarthritis pain
- Stress urinary incontinence
- Cardiovascular and renal outcomes
These future orforglipron clinical trials will continue to expand understanding of the medication's potential benefits and applications.
Conclusion
The orforglipron clinical trials program represents one of the most comprehensive evaluations of an oral GLP-1 medication. The orforglipron clinical trial results from Phase 3 studies provide robust evidence supporting efficacy and safety.
Key orforglipron clinical trials including ACHIEVE-1, ACHIEVE-3, ATTAIN-1, and ATTAIN-2 have demonstrated significant benefits in type 2 diabetes and obesity treatment. The orforglipron phase 3 program's comprehensive design and execution support the medication's potential as an important therapeutic option.
As additional orforglipron clinical trial results become available, the understanding of this medication's role in clinical practice will continue to evolve, potentially expanding treatment options for patients with type 2 diabetes and obesity.